Clinical Supply Manufacturing Marketing Reagent 
Pharmaceutical Technology
APRIL 28, 2023
The company undertook several initiatives recently to expand its business through new partnerships, expansion of existing relationships, and investment in manufacturing capacity. Initially centered on Librela®, this agreement paves the way for developing and manufacturing other molecules in the coming years. until 2026.
Drug Discovery World
MARCH 13, 2023
The individual successes within the CGT market are impressive, but this therapeutic class remains unattainable to the vast majority of the world. Before 2019, CGT drug developers still had a young, academic mindset, ordering reagents, materials, and equipment haphazardly and assuming they would show up when needed.
Expert insights. Personalized for you.
130 
Let's personalize your content